LiMM Therapeutics

LiMM Therapeutics was a private biopharmaceutical company developing first-in-class immunology therapies based on neuroimmune crosstalk between neurons and innate lymphoid cells in peripheral tissues. The company’s core concept was its NRIL platform, or neuronal reprogrammers of innate lymphocytes, aimed at preserving tissue health and treating inflammatory, infectious, metabolic, and oncology-related conditions. Public descriptions of the lead translational effort emphasized preclinical work in acute kidney injury and inflammation, with plans supported by European Innovation Council funding to advance into human studies. The company was founded out of research associated with Henrique Veiga-Fernandes and operated from Paris, with scientific activities linked to the Champalimaud ecosystem in Portugal. More recent business intelligence and insolvency-related sources indicate the company is no longer active, and its website/domain is no longer operating as a company site.